Keros Therapeutics, Inc.
10-K
March 4, 2026
Key Highlights
- Promising early clinical data for lead drug candidates KER-050 (MDS) and KER-012...
- Strong cash position of $285.7 million with an estimated cash runway until mid-2...
- Strategic focus on rare diseases, leveraging a unique TGF-ß protein family platf...
Read Analysis
🤖 AI Generated